Safety and Pharmacokinetics of Nebulized Laninamivir Octanoate, A Long Acting Neuraminidase Inhibitor, In Healthy Subjects

Background A single inhaled dosing of laninamivir octanoate (LO) using a dry powder inhaler (DPI) exhibits appropriate efficacy to treat both adult and pediatric patients with influenza virus infection. Herein is described a single dose ascending study in healthy subjects to evaluate the safety and...

Full description

Saved in:
Bibliographic Details
Published inClinical Therapeutics Vol. 39; no. 8; pp. e25 - e26
Main Authors Toyama, K., Furuie, H., Ishizuka, H.
Format Journal Article
LanguageEnglish
Published Bridgewater Elsevier Inc 01.08.2017
Elsevier BV
Elsevier Limited
Subjects
Exo-a-sialidase
Influenza
Internal Medicine
Medical Education
Pharmacokinetics
Online AccessGet full text
ISSN0149-2918
1879-114X
DOI10.1016/j.clinthera.2017.05.078

Cover

More Information
Summary:Background A single inhaled dosing of laninamivir octanoate (LO) using a dry powder inhaler (DPI) exhibits appropriate efficacy to treat both adult and pediatric patients with influenza virus infection. Herein is described a single dose ascending study in healthy subjects to evaluate the safety and pharmacokinetics of LO and laninamivir,...
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2017.05.078